View PDF Edition - U.S. Pharmacist

More documents

Recommendations

Info

BRIEF SUMMARY OF FULL PRESCRIBING INFORMATIONKAPIDEX (dexlansoprazole) delayed release capsulesINDICATIONS AND USAGEKAPIDEX is indicated for: CONTRAINDICATIONS [see Adverse Reactions]WARNINGS AND PRECAUTIONSGastric Malignancy ADVERSE REACTIONSClinical Trials Experience Table 2: Incidence of Treatment-Emergent AdverseReactions in Controlled StudiesPlaceboKAPIDEX30 mg(N=455)%KAPIDEX60 mg(N=2218)%KAPIDEXTotal(N=2621)%Lansoprazole30 mg(N=1363)%(N=896)Adverse Reaction % Tract Infection Blood and Lymphatic System Disorders: CardiacDisorders: Ear and Labyrinth Disorders: Endocrine Disorders: Eye Disorders: Gastrointestinal Disorders: General Disorders and Administration Site Conditions: Hepatobiliary Disorders: Immune System Disorders: Infections and Infestations: Injury, Poisoning and Procedural Complications: Laboratory Investigations: Metabolism and NutritionDisorders: Musculoskeletaland Connective Tissue Disorders: Nervous System Disorders: PsychiatricDisorders: Renal and Urinary Disorders: ReproductiveSystem and Breast Disorders: ; Respiratory, Thoracic and Mediastinal Disorders: Skin and Subcutaneous TissueDisorders: Vascular Disorders: DRUG INTERACTIONSDrugs with pH-Dependent Absorption Pharmacokinetics Warfarin USE IN SPECIFIC POPULATIONSPregnancyTeratogenic Effects
Nursing Mothers [see Carcinogenesis, Mutagenesis, Impairment of Fertility] Pediatric Use Geriatric Use ]Renal Impairment .Hepatic Impairment .OVERDOSAGE CLINICAL PHARMACOLOGYPharmacodynamics [see Nonclinical Toxicology ] c c NONCLINICAL TOXICOLOGYCarcinogenesis, Mutagenesis, Impairment of Fertility [see Clinical Pharmacology]. PATIENT COUNSELING INFORMATION[see FDA-Approved Patient Labeling in the full prescribing information]Information for Patients Takeda Pharmaceuticals America, Inc. KAPIDEX and Dual Delayed Release are trademarks of Takeda Pharmaceuticals North America, Inc.,and are used under license by Takeda Pharmaceuticals America, Inc.Reference: 1. KAPIDEX (dexlansoprazole) package insert, Takeda Pharmaceuticals America, Inc.©2009 Takeda Pharmaceuticals North America, Inc.LPD-00250 6/09 Printed in U.S.A.
Page 5 and 6:
USE IN SPECIFIC POPULATIONSPregnanc
Page 7 and 8:
U.S. PharmacistWhat’s NewsEditori
Page 9 and 10:
Q. Which Global Generic Company’s
Page 11 and 12:
If key productsare missing from you
Page 13 and 14:
1,500+ WaysWe Meet Your Needs
Page 15 and 16:
✁PATIENT INFORMATIONCombating Fat
Page 17 and 18:
Consult Your Pharmacistsleep, wheth
Page 19 and 20:
PATIENT TEACHING AIDBipolarDisorder
Page 21 and 22:
Our most important ingredient is in
Page 23 and 24:
IN THE TREATMENT OF MRSA BACTEREMIA
Page 25 and 26:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 28 and 29:
SCHIZOPHRENIA: A REVIEW OF TREATMEN
Page 30 and 31: HEALTH SYSTEMS EDITION© JUPITERIMA
Page 32 and 33: FENTANYL TRANSDERMAL SYSTEMBRIEF SU
Page 34 and 35: other opioids, or to subtract the f
Page 36: TRAUMATIC BRAIN INJURYHEALTH SYSTEM
Page 40 and 41: HEALTH SYSTEMS EDITIONNewly Approve
Page 42 and 43: HEALTH SYSTEMS EDITIONMTOR INHIBITO
Page 48 and 49: HEALTH SYSTEMS EDITIONIn-Service Pr
Page 50 and 51: NUTRITION AND CLINICAL DEPRESSIONHE
Page 52 and 53: NUTRITION AND CLINICAL DEPRESSIONHE
Page 54: NUTRITION AND CLINICAL DEPRESSIONHE
Page 57 and 58: PROGRESSIVE SUPRANUCLEAR PALSYlabil
Page 60 and 61: FDA Fast FactsNew LeukemiaTreatment
Page 62: So Many Options,So Little Differenc
Page 66: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 75 and 76: WHAT IS THE APPROPRIATE ANTIDEPRESS
Page 77 and 78: OPIOID MAINTENANCE TREATMENTTable 1
Page 79: KAPIDEX is the first and only PPI w
Page 83 and 84: Table 3Potential Drug Interactions
Page 85 and 86: Providing Affordable andInnovative
Page 87 and 88: GREENSTONELLCWatch Our Product Line
Page 89 and 90: Contemporary Compoundinglevel in le
Page 91 and 92: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 93 and 94: Zmax: 1 product — indicated for b
Page 95 and 96: PHARMACOLOGIC MANAGEMENT OF ALCOHOL
Page 97 and 98: CRIMINALIZATION OF MEDICATION ERROR
Page 99 and 100: &are excited to launch:www.PharmQD.
Page 101 and 102: Table 1Early Barriers PreventingUti
Page 103 and 104: EMERGENCY CONTRACEPTION: AN UPDATEo
Page 105 and 106: EMERGENCY CONTRACEPTION: AN UPDATEs
Page 107 and 108: EMERGENCY CONTRACEPTION: AN UPDATE1
Page 109 and 110: Examination Answer SheetCredits: 2.
Page 111 and 112: U.S. Pharmacist ClassifiedsCAREER O
Page 113 and 114: ONGLYZA (saxagliptin) tabletsBrief
show all

View PDF Edition - U.S. Pharmacist

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?